[go: up one dir, main page]

MA31117B1 - Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes - Google Patents

Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes

Info

Publication number
MA31117B1
MA31117B1 MA32127A MA32127A MA31117B1 MA 31117 B1 MA31117 B1 MA 31117B1 MA 32127 A MA32127 A MA 32127A MA 32127 A MA32127 A MA 32127A MA 31117 B1 MA31117 B1 MA 31117B1
Authority
MA
Morocco
Prior art keywords
corticosteroids
receptor modulators
tricyclic compounds
compounds
salts
Prior art date
Application number
MA32127A
Other languages
Arabic (ar)
English (en)
Inventor
Rajesh Venkateswaran Devraj
Crescenzo Gary A De
Xiao Hu
Kevin Dewayne Jerome
Mark Gerard Obukowicz
Lisa Olson
Paul Vincent Rucker
Ronald Keith Webber
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA31117B1 publication Critical patent/MA31117B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)

Abstract

La présente invention concerne des composés de formule (i), ou leurs sels, qui sont des modulateurs du récepteur des glucocorticoïdes. Les composés et les sels de l'invention sont utiles dans le traitement d'affections médiées par l'activité des récepteurs des glucocorticoïdes.
MA32127A 2007-02-02 2009-07-31 Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes MA31117B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88798107P 2007-02-02 2007-02-02
PCT/IB2008/000229 WO2008093227A1 (fr) 2007-02-02 2008-01-25 Composés tricycliques et leur utilisation en tant que modulateurs des récepteurs des glucocorticoïdes

Publications (1)

Publication Number Publication Date
MA31117B1 true MA31117B1 (fr) 2010-01-04

Family

ID=39315208

Family Applications (2)

Application Number Title Priority Date Filing Date
MA32128A MA31158B1 (fr) 2007-02-02 2009-07-31 Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes
MA32127A MA31117B1 (fr) 2007-02-02 2009-07-31 Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA32128A MA31158B1 (fr) 2007-02-02 2009-07-31 Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes

Country Status (42)

Country Link
US (7) US7547714B2 (fr)
EP (1) EP2114970B1 (fr)
JP (1) JP4599462B2 (fr)
KR (2) KR101107949B1 (fr)
CN (2) CN101616925B (fr)
AP (1) AP2455A (fr)
AR (2) AR065135A1 (fr)
AT (1) ATE518872T1 (fr)
AU (1) AU2008211613B2 (fr)
BR (1) BRPI0808634A2 (fr)
CA (1) CA2676670C (fr)
CL (2) CL2008000329A1 (fr)
CO (2) CO6220937A2 (fr)
CR (2) CR10948A (fr)
CU (2) CU20090133A7 (fr)
CY (2) CY1110962T1 (fr)
DK (1) DK2114970T3 (fr)
DO (1) DOP2009000190A (fr)
EA (1) EA016494B1 (fr)
EC (2) ECSP099552A (fr)
ES (2) ES2368286T3 (fr)
GE (2) GEP20125404B (fr)
GT (2) GT200900210A (fr)
HN (2) HN2008000178A (fr)
HR (1) HRP20110702T1 (fr)
IL (1) IL199972A (fr)
MA (2) MA31158B1 (fr)
MX (1) MX2009008284A (fr)
MY (3) MY153057A (fr)
NI (2) NI200900149A (fr)
NZ (1) NZ578638A (fr)
PE (2) PE20081736A1 (fr)
PL (1) PL2114970T3 (fr)
PT (2) PT2114970E (fr)
RS (2) RS51970B (fr)
SI (1) SI2114970T1 (fr)
SV (2) SV2009003346A (fr)
TN (1) TN2009000324A1 (fr)
TW (2) TWI347842B (fr)
UA (2) UA94639C2 (fr)
WO (1) WO2008093227A1 (fr)
ZA (2) ZA200906060B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0934061B3 (fr) 1996-07-24 2015-01-21 Warner-Lambert Company LLC Isobutylgaba et ses derives utilises pour le traitement de la douleur
KR101107949B1 (ko) 2007-02-02 2012-02-08 화이자 프로덕츠 인코포레이티드 트라이사이클릭 화합물 및 글루코코르티코이드 수용체 조절자로서의 이들의 용도
PE20110559A1 (es) * 2008-07-28 2011-08-06 Pfizer (4bR,6R,7R,8aS)-4b-BENCIL-6,7-DIHIDROXI-6-METIL-N-(2-METILPIRIDIN-3-IL)-10-OXO-7-FENIL-4b,5,6,7,8,8a,9,10-OCTAHIDROFENANTRENO-2-CARBOXAMIDA COMO MODULADOR DEL RECEPTOR GLUCOCORTICOIDE
US8765787B2 (en) * 2008-11-21 2014-07-01 Bridge Pharma, Inc. Methods of treatment of xerophthalmia with self-preserving ocular formulations of norketotifen
US20100136094A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100136097A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100136095A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100137787A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Delivery devices for modulating inflammation
US20100136096A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100135983A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
US20100137246A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
US20130116284A1 (en) 2010-05-10 2013-05-09 Radikal Therapeutics Inc. Lipoic acid and nitroxide derivatives and uses thereof
AU2011293193A1 (en) * 2010-08-27 2013-02-14 Corcept Therapeutics, Inc. Pyridyl-amine fused azadecalin modulators
KR20140015472A (ko) * 2011-03-15 2014-02-06 애브비 인코포레이티드 핵 호르몬 수용체 조절제
US8545904B1 (en) 2012-06-05 2013-10-01 Liquid Innovators, LLC Topical composition containing Carapa (andiroba) oil for psoriasis and other related dermatological disorders
US9227901B2 (en) 2012-07-05 2016-01-05 Abbvie Inc. Process for preparing bicyclic amine derivatives
TW201422590A (zh) 2012-09-07 2014-06-16 Abbvie Inc 雜環核激素受體調節劑
WO2014094357A1 (fr) 2012-12-21 2014-06-26 Abbvie Inc. Modulateurs hétérocycliques des récepteurs nucléaires aux hormones
CN113712838A (zh) 2014-05-16 2021-11-30 奥拉普莱克斯股份有限公司 角蛋白处理制剂和方法
SG10202011669PA (en) 2014-10-20 2020-12-30 Oyster Point Pharma Inc Methods of treating ocular conditions
CN104591988A (zh) * 2014-12-29 2015-05-06 甘肃省化工研究院 6-溴-2-萘满酮的合成方法
FI3273955T3 (fi) * 2015-03-23 2025-12-12 Tianli Biotech Pty Ltd Hengityselinsairauksien hoito
MX385698B (es) 2016-04-07 2025-03-18 Oyster Point Pharma Inc Uso de un compuesto que comprende un grupo pirrolidinilo y pirimidinilo para tratar enfermedades oculares
WO2020093097A1 (fr) 2018-11-07 2020-05-14 The University Of Melbourne Composés et compositions pour le traitement de maladies respiratoires

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2576025B1 (fr) 1985-01-14 1987-01-23 Roussel Uclaf Nouveaux steroides substitues en position 10, leur procede et les intermediaires de preparation, leur application comme medicaments, les compositions pharmaceutiques les contenant
FR2600450B1 (fr) * 1986-06-19 1988-08-26 Pechiney Aluminium Procede de marquage individuel des anodes precuites pour la production electrolytique d'aluminium
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
IL122740A (en) 1997-01-15 2003-09-17 Akzo Nobel Nv 16-hydroxy-11-(substituted phenyl)-estra-9,4-diene derivatives, their preparation and pharmaceutical compositions containing them
NZ514465A (en) 1999-04-30 2003-11-28 Pfizer Prod Inc Glucocorticoid receptor modulators
WO2001005229A1 (fr) 1999-07-15 2001-01-25 The General Hospital Corporation Vecteur viral d'epstein-barr non defectueux
IL146057A (en) * 2000-10-27 2007-09-20 Pfizer Prod Inc A process for the preparation of modulators of a non-steroidal glucocorticoid receptor
JP2002193911A (ja) 2000-10-28 2002-07-10 Pfizer Prod Inc グルココルチコイドレセプターモジュレーター
ES2246292T3 (es) 2000-10-30 2006-02-16 Pfizer Products Inc. Moduladores de receptor glucocorticoide.
KR100793464B1 (ko) * 2000-11-20 2008-01-14 시게이트 테크놀로지 엘엘씨 Ｒｆｉｄ 태그 및 이를 디스크 드라이브에 부착하는 방법
AU2002309172A1 (en) 2001-06-22 2003-01-08 Pfizer Products Inc. Pharmaceutical compositions containing polymer and drug assemblies
CN1868480A (zh) 2001-08-31 2006-11-29 科塞普特治疗公司 抑制成年唐氏综合症患者认知退化的方法
WO2003029217A2 (fr) 2001-09-27 2003-04-10 Universite De Liege Derives de sulfonamide pyridinique, procede de fabrication et d'utilisation
DE10164366C1 (de) * 2001-12-28 2003-06-05 Rehau Ag & Co Permanentkathode
DE60320940D1 (de) 2002-02-01 2008-06-26 Pfizer Prod Inc Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
US8476254B2 (en) 2002-07-02 2013-07-02 Corcept Therapeutics, Inc. Methods for treating psychosis associated with interferson-α therapy
MXPA05000345A (es) 2002-07-08 2005-03-31 Pfizer Prod Inc Moduladores del receptor de glucocorticoides.
JP2006507311A (ja) 2002-11-05 2006-03-02 コーセプト セラピューティクス， インコーポレイテッド 胃食道逆流性疾患を処置するための方法
JP2006516651A (ja) 2003-02-04 2006-07-06 コーセプト セラピューティクス， インコーポレイテッド 産後精神病の処置のための抗糖質コルチコイド
US8097606B2 (en) 2003-07-23 2012-01-17 Corcept Therapeutics, Inc. Antiglucocorticoids for the treatment of catatonia
US20050080061A1 (en) 2003-07-23 2005-04-14 Corcept Therapeutics, Inc. Antiglucocorticoid therapy for the prevention of neurological damage in premature infants
TW200512181A (en) 2003-09-26 2005-04-01 Tanabe Seiyaku Co Amide-type carboxamide derivatives
US7592177B2 (en) * 2003-11-10 2009-09-22 The Scripps Research Institute Compositions and methods for inducing cell dedifferentiation
CA2545020A1 (fr) * 2003-11-13 2005-05-26 Pfizer Products Inc. Derives d'octahydro-phenanthrene-hydrazide utiles en tant que modulateurs du recepteur des glucocorticoides
TWI370129B (en) 2005-02-14 2012-08-11 Msd Oss Bv Non steroidal glucocorticoid receptor modulators
AU2007248059A1 (en) 2006-05-02 2007-11-15 Corcept Therapeutics, Inc. The use of a glucocorticoid receptor ii antagonist to treat depression in patients taking il-2
WO2008093236A1 (fr) * 2007-02-02 2008-08-07 Pfizer Products Inc. Composés tricycliques et leur utilisation en tant que modulateurs des récepteurs des glucocorticoïdes
KR101107949B1 (ko) 2007-02-02 2012-02-08 화이자 프로덕츠 인코포레이티드 트라이사이클릭 화합물 및 글루코코르티코이드 수용체 조절자로서의 이들의 용도

Also Published As

Publication number Publication date
EP2114970B1 (fr) 2011-08-03
IL199972A (en) 2013-09-30
HN2008000178A (es) 2011-02-25
US8901310B2 (en) 2014-12-02
BRPI0808634A2 (pt) 2014-08-05
CR10948A (es) 2009-08-07
AU2008211613A1 (en) 2008-08-07
TW200838514A (en) 2008-10-01
CO6220937A2 (es) 2010-11-19
PE20090113A1 (es) 2009-02-13
US8445520B2 (en) 2013-05-21
CU23824A3 (es) 2011-10-31
AR065134A1 (es) 2009-05-20
CR10949A (es) 2009-08-07
CY1111758T1 (el) 2015-10-07
DK2114970T3 (da) 2011-09-19
US7547714B2 (en) 2009-06-16
AP2009004942A0 (en) 2009-08-31
TW200846325A (en) 2008-12-01
ZA200906060B (en) 2010-05-26
SV2009003346A (es) 2010-04-13
MX2009008284A (es) 2009-08-12
CN101616925A (zh) 2009-12-30
KR20090107080A (ko) 2009-10-12
GEP20125404B (en) 2012-02-27
US20140142316A1 (en) 2014-05-22
CU20090132A7 (es) 2011-10-14
SI2114970T1 (sl) 2011-11-30
US20080188443A1 (en) 2008-08-07
GT200900210A (es) 2010-04-05
UA95332C2 (uk) 2011-07-25
GT200900209A (es) 2010-07-22
ES2368286T3 (es) 2011-11-16
CN101616896A (zh) 2009-12-30
ECSP099552A (es) 2009-08-28
PE20081736A1 (es) 2008-11-28
US8158660B2 (en) 2012-04-17
MY148780A (en) 2013-05-31
MY146087A (en) 2012-06-29
HK1135108A1 (en) 2010-05-28
CU23848B1 (es) 2012-10-15
US7598231B2 (en) 2009-10-06
RS51970B (sr) 2012-02-29
DOP2009000190A (es) 2009-08-31
TN2009000324A1 (fr) 2010-12-31
WO2008093227A1 (fr) 2008-08-07
CO6190603A2 (es) 2010-08-19
US20080312294A1 (en) 2008-12-18
HRP20110702T1 (hr) 2011-10-31
MY153057A (en) 2014-12-31
JP4599462B2 (ja) 2010-12-15
US20120095062A1 (en) 2012-04-19
US20140316139A1 (en) 2014-10-23
CN101616925B (zh) 2012-05-23
PT2114888E (pt) 2011-01-04
KR101107949B1 (ko) 2012-02-08
EA200970666A1 (ru) 2010-02-26
KR101114682B1 (ko) 2012-03-14
IL199972A0 (en) 2010-04-15
KR20090108115A (ko) 2009-10-14
PL2114970T3 (pl) 2011-11-30
PT2114970E (pt) 2011-09-22
RS51646B (sr) 2011-10-31
EA016494B1 (ru) 2012-05-30
CN101616896B (zh) 2012-07-04
US7786097B2 (en) 2010-08-31
AR065135A1 (es) 2009-05-20
US20100286214A1 (en) 2010-11-11
US20090281148A1 (en) 2009-11-12
CA2676670C (fr) 2012-03-13
HN2008000179A (es) 2010-06-09
CU20090133A7 (es) 2011-10-31
EP2114970A1 (fr) 2009-11-11
UA94639C2 (ru) 2011-05-25
TWI347842B (en) 2011-09-01
TWI373466B (en) 2012-10-01
ATE518872T1 (de) 2011-08-15
AU2008211613B2 (en) 2013-05-23
CY1110962T1 (el) 2015-06-11
NI200900148A (es) 2010-02-15
CL2008000329A1 (es) 2008-08-08
SV2009003349A (es) 2010-04-13
MA31158B1 (fr) 2010-02-01
US20120088802A9 (en) 2012-04-12
ZA200906064B (en) 2010-05-26
CL2008000330A1 (es) 2008-08-08
CA2676670A1 (fr) 2008-08-07
AP2455A (en) 2012-08-31
ECSP099553A (es) 2009-08-28
ES2353822T3 (es) 2011-03-07
GEP20125426B (en) 2012-03-26
NZ578638A (en) 2010-12-24
JP2010517990A (ja) 2010-05-27
NI200900149A (es) 2010-02-15

Similar Documents

Publication Publication Date Title
MA31117B1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes
MA31906B1 (fr) Inhibiteurs de la replication du virus de limmunodeficience humaine
MA34650B1 (fr) Antagonistes du récepteur cgrp de pipéridinone carboxamide azaindane
MA32466B1 (fr) Derives de triazole utiles pour le traitement de maladies
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
MA34474B1 (fr) Agonistes de gpr40
MA33155B1 (fr) Composes organiques et leurs utilisations
MA35750B1 (fr) Dérivés de nucléoside substitué 2',4'-difluoro-2'-méthyle en tant qu'inhibiteurs de la réplication de l'arn du vhc (virus de l'hépatite c)
EP2004177A4 (fr) Composes de nitrofurane utilises dans le traitement du cancer et de l'angiogenese
MA33730B1 (fr) Procédés de synthèse pour des composés spiro-oxindoles
EA200602243A1 (ru) 3-аминоциклопентанкарбоксамиды в качестве модуляторов хемокиновых рецепторов
EA200970065A1 (ru) Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38
MA30077B1 (fr) 3-aminocyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines
MA38315A1 (fr) Composés tétracycliques substitués par un hétérocycle et procédés pour les utiliser pour le traitement de maladies virales
EP2091328A4 (fr) Composés de spiropipéridine inhibiteurs de la bêta-sécrétase pour le traitement de la maladie d'alzheimer
EA200602242A1 (ru) 3-аминоциклопентанкарбоксамиды в качестве модуляторов хемокиновых рецепторов
MA34545B1 (fr) Co-cristaux et sels d'inhibiteurs de ccr3
MA33242B1 (fr) Composes pour le traitement de troubles metaboliques
EP2563794A4 (fr) Inhibiteurs de l'activité protéine tyrosine kinase et leurs applications au traitement de troubles ophtalmiques
EA200700909A1 (ru) Азаиндолкарбоксамиды
DE602006019911D1 (de) Mglur1-antagonisten als therapeutische wirkstoffe
MX2009008286A (es) Compuestos triciclicos y su uso como moduladores del receptor de glucocorticosteroides.
MA39253B1 (fr) Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr
IL189974A0 (en) Benzimidazole derivatives and their use for modulating the gabaa receptor complex
ATE525370T1 (de) Phthalazin- und pyridoä3,4- düpyridazinverbindungen als h1-rezeptor- antagonisten